MGNX News and Press, MacroGenics Inc. From 11/30/20

MacroGenics (MGNX) has received $25M in milestone payment from Incyte (INCY), related to retifanlimab, an investigational anti-PD-1 monoclonal antibody designed by MacroGenics and licensed to Incyte (as INCMGA0012). The payment was triggered by recent initiation of POD1UM-303, ...

ROCKVILLE, MD, Nov. 30, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that $25 million in mileston...

MacroGenics is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for immune-response modulation for treating cancer. MacroGenics's pipeline consists of 7 therapeutics with all 7 in clinical phases covering various cancers with Margetuximab, t...

The following slide deck was published by MacroGenics, Inc. in conjunction with their 2020 Q3 earnings call. For further details see: MacroGenics, Inc. 2020 Q3 - Results - Earnings Call Presentation

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...

MacroGenics, Inc. (MGNX) Q3 2020 Earnings Conference Call November 04, 2020 04:30 PM ET Company Participants Anna Krassowska - Investor Relations Scott Koenig - President and CEO Jim Karrels - CFO Stephen Eck - CMO Conference Call Participants Yigal Nochomovitz - Citigroup Evan Seigerman - Cr...

Image source: The Motley Fool. MacroGenics (NASDAQ: MGNX) Q3 2020 Earnings Call Nov 04, 2020 , 4:30 p.m. ET Operator Continue reading For further details see: MacroGenics (MGNX) Q3 2020 Earnings Call Transcript

MacroGenics (MGNX): Q3 GAAP EPS of -$0.66 beats by $0.29.Revenue of $18.25M (-2.6% Y/Y) beats by $4.46M.Press Release For further details see: MacroGenics EPS beats by $0.29, beats on revenue

ROCKVILLE, Md., Nov. 04, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today provided an update on its corporate progr...

ROCKVILLE, MD, Nov. 04, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced six clinical and preclinica...